In recent years there has been methodological improvement in established nuclear medicine procedures, such as renal and skeletal scintigraphy and new very specific probes for treatment and diagnosis of urological diseases have been introduced into the clinical routine.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
New diagnostic methods, such as positron emission tomography (PET) using prostate-specific membrane antigen (PSMA) ligands for highly accurate tumor localization in recurrent prostate cancer have become available in many centers The very high and selective accumulation of these PSMA ligands in tumor tissue has shown promising therapeutic results Moreover, since 2013 a new radiopharmaceutical agent, radium-223 dichloride, has been approved for treatment of symptomatic bone metastases of prostate cancer Better knowledge of indications, benefits and limitations of these procedures will help clinicians to adequately introduce them into patient management This article summarizes the state of the art in established nuclear medicine procedures for urological disorders and also reports on new diagnostic and therapeutic possibilities
Der Urologe Ausg A 2015 Jul [Epub]
W P Fendler, V Wenter, C G Stief, C Gratzke, P Bartenstein
Klinik und Poliklinik für Nuklearmedizin, Ludwig-Maximilians-Universität München, Marchioninistr 15, 81377, München, Deutschland